Patents by Inventor Simon Plyte

Simon Plyte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antagonizing CD73 antibody
    Patent number: 11312785
    Abstract: The present invention relates to novel antagonizing antibodies for CD73. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 26, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Irmgard Maria Rita Hofmann, Jennifer Ahlberg, Rajkumar Ganesan, Priyanka Gupta, Sven Mostboeck, Simon Plyte, Otmar Schaaf, Chia-Hung Tsai, Melanie Wurm, Markus Zettl, Jark Boettcher, Bruna De Andrade Pereira
  • Antagonizing CD73 Antibody
    Publication number: 20190352420
    Abstract: The present invention relates to novel antagonizing antibodies for CD73. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: May 13, 2019
    Publication date: November 21, 2019
    Inventors: Irmgard Maria Rita HOFMANN, Jennifer AHLBERG, Rajkumar GANESAN, Priyanka Gupta, Sven MOSTBOECK, Simon PLYTE, Otmar SCHAAF, Chia-Hung TSAI, Melanie WURM, Markus ZETTL, Jark BOETTCHER, Bruna DE ANDRADE PEREIRA
  • Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition
    Patent number: 8669261
    Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: March 11, 2014
    Assignee: Congenia SLR
    Inventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
  • ACRYLOMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION
    Publication number: 20130245019
    Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 30, 2013
    Publication date: September 19, 2013
    Applicant: CONGENIA SRL
    Inventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
  • Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
    Patent number: 8470831
    Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: June 25, 2013
    Assignee: Cogenia SRL
    Inventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
  • ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION
    Publication number: 20110195977
    Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.
    Type: Application
    Filed: September 23, 2009
    Publication date: August 11, 2011
    Inventors: Daniele Fancelli, Varasi Mario, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
  • Human homologue of the DBF4/ASK1 protein, nucleic acids, and methods related to the same
    Patent number: 7259244
    Abstract: The present invention provides a human polypeptide homolog of DBF4/ASK1 (for “Activator of S phase kinase”) and polynucleotides which identify and encode DRF1 (for “DBF4 Related Factor 1”). In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of DRF1 or DRF1-containing complex agonists/antagonists, useful for the treatment of human diseases and conditions.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: August 21, 2007
    Assignee: Nerviano Medical Sciences S.R.L.
    Inventors: Jens Berthelsen, Roberta Bosotti, Antonella Isacchi, Simon Plyte
  • Novel human homologue of the dbf4/ask1 protein, nucleic acids, and methods related to the same
    Publication number: 20040102611
    Abstract: The present invention provides a human polypeptide homolog of DBF4/ASK1 and polynucleotides which identify and encode DRF1. In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of DRF1 or DRF1-containing complex agonists/antagonists, useful for the treatment of human diseases and conditions.
    Type: Application
    Filed: June 27, 2003
    Publication date: May 27, 2004
    Inventors: Jens Bethelsen, Roberta Bosotti, Antonella Isacchi, Simon Plyte